SAN DIEGO, April 1, 2019 – Primmune Therapeutics today announced that it will present preclinical data on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. The research demonstrates the potential of our oral TLR7 agonists to improve response rates and treatment durability.

“There is a very strong rationale for combining agents that activate innate immunity, like TLR7 agonists, with drugs that engage adaptive immunity, like checkpoint inhibitors. This approach has the potential to address patients who inadequately respond to approved treatments,” said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics. “Our program builds upon historical clinical experience with TLR7 agonists, which we used to identify an ideal pharmacologic profile. We believe that long-term systemic dosing with TLR7 agonists best complements adaptive immunity approaches and we’ve discovered compounds that fulfill these requirements in preclinical testing.”

Poster presentation details:

Title: 3262 / 12 – Discovery of a series of novel toll-like receptor 7 agonists for systemic immunotherapy of cancer
Presenter: James R. Appleman, Ph.D.
Session: PO.IM02.11 – Novel Immunomodulatory Agents 1
Date and time: April 2, 2019 from 8:00 AM – 12:00 PM ET

About Primmune Therapeutics

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.